key: cord-0912298-9glhbciy authors: Laura, Gianotti; Salvatore, D’Agnano; Giorgio, Pettiti; Francesco, Tassone; Giorgio, Giraudo; Corrado, Lauro; Giuseppe, Lauria; Valerio, Del Bono; Giorgio, Borretta title: Persistence of Elevated Procalcitonin in a Patient with Covid-19 Uncovering a Diagnosis of Medullary Thyroid Carcinoma date: 2021-05-12 journal: AACE Clin Case Rep DOI: 10.1016/j.aace.2021.05.001 sha: 3168c2d0ede260dc26a924dd44a87e1d386063a2 doc_id: 912298 cord_uid: 9glhbciy OBJECTIVES: During this ongoing pandemic of coronavirus disease 2019 (COVID-19), procalcitonin (PCT) assay has proven to be a useful tool in assisting clinicians to diagnose bacterial superinfection. However, in the absence of signs of infection or at resolution thereof, inappropriately and persistently high PCT may suggest and reveal the presence of other pathologies. We report a patient with acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia in whom persistence of initially elevated PCT during recovery prompted the diagnosis of medullary thyroid cancer (MTC). CASE REPORT: A 43- year-old man presented with a two-day history of fever, sneezing, sore throat and dry cough. Physical exam revealed decreased sounds and coarse crackles in both lung bases at auscultation. Medical history was positive for cognitive impairment since birth, arterial hypertension, systemic lupus erythematosus with nephritis. Initial studies included mild lymphocytopenia 650/μl (760 – 5000), D-Dimer 0.73 μg/ml (< 0.5), C reactive protein (CRP) of 62 mg/l (< 5) and PCT of 94 ng/ml (0.00 – 0.10). Positivity for SARS-Cov-2 RNA was detected and chest computerized tomography showed bilateral ground-glass opacities in the basilar lung zones and hyperdense and irregular foci in the thoracic vertebral bodies. Empirical antibiotic therapy was started and was maintained for seven days but, despite clinical improvement and the normalization of CRP, serum PCT was persistently high (84 ng/ml). Serum calcitonin (CTN) was 2120 pg/ml (normal up to 12 pg/ml). Neck ultrasound revealed inhomogeneously echogenic lymph nodes with small punctate calcifications and a non-homogeneous thyroid with multiple nodules. Cytological examination by fine needle aspiration and CTN measurement on washing liquid confirmed the suspicion of MTC. The patient underwent total thyroidectomy with bilateral cervical lymph node dissection. Histological analysis confirmed MTC of right thyroid lobe and metastasis at lymph nodes of the central right midneck area. Blood tests performed 48 hours after surgery showed a lowering of CTN (986 pg/mL) and PCT (16 ng/mL). A 6-months follow up showed persistent increased CTN and PCT levels (921 pg/ml and 16 ng/ml, respectively) while a (18)F-fluorodihydro-xyphenylalanine ((18)F-DOPA) PET did not reveal any suspicious fixations at thyroid lodge and cervical lymph node stations while multiple osteoblastic foci in the skeletal area were described. A close follow-up was planned with establishment of the results of RET gene analysis. DISCUSSION: Although CTN is the gold standard biochemical parameter for the diagnosis and follow-up of MTC, PCT can be useful as a biochemical marker of MTC suspicion in patients with inflammatory conditions and persistently elevated PCT even after resolution. In the present CASE, high levels of PCT in a patient with Covid-19 pneumonia without signs of bacterial infection, allowed to diagnose MCT. CONCLUSION: In the absence of any other signs of infection, a complete clinical assessment, including neck palpation, CTN measurement and thyroid ultrasound should be performed in the presence of persistently elevated PCT. Authors Gianotti Laura, D'Agnano Salvatore*, Pettiti Giorgio**, Tassone Francesco, Giraudo 4 Giorgio***, Lauro Corrado***, Lauria Giuseppe****, Del Bono Valerio**, Borretta Giorgio. 5 6 Short title (running head): procalcitonin in medullary thyroid carcinoma 7 8 9 Affiliations Medullary thyroid carcinoma (MTC) is a neuroendocrine neoplasia deriving from thyroid 95 parafollicular or C-cells, accounting for about 5% of all thyroid cancers. Its peak incidence is during 96 early adulthood (1,2). Calcitonin (CTN), a peptide that results from the cleavage and post 97 translational processing of procalcitonin (PCT), is the main product of the C-cells of the thyroid 98 gland and acts to reduce blood calcium thus opposing the effects of the parathyroid hormone (PTH). 99 CTN measurement is, to date, the most sensitive diagnostic test for identifying patients with MTC 100 and C-cell hyperplasia and it is a marker for residual or recurrent disease in MTC (2). 101 PCT, the CTN precursor, is found in low serum concentrations in healthy individuals whereas the 102 production and release into circulation from extrathyroidal sources, such as immune cells or liver, Medullary thyroid carcinoma Thyroid Association guidelines for the management of medullary thyroid carcinoma The diagnostic accuracy of 252 procalcitonin for bacteraemia: a systematic review and meta-analysis Procalcitonin: Where Are We Now? Crit Care Clin 256 5. FDA. FDA clears test to help manage antibiotic treatment for lower respiratory tract 257 infections and sepsis Procalcitonin to 261 initiate or discontinue antibiotics in acute respiratory tract infections Procalcitonin measurement to screen medullary thyroid carcinoma: A prospective evaluation 265 in a series of 2705 patients with thyroid nodules Procalcitonin for detecting 267 medullary thyroid carcinoma: a systematic review The Journal of clinical endocrinology and 274 metabolism. United States Laboratory Testing in Thyroid Conditions -Pitfalls and Clinical Utility Procalcitonin: 278 a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma Procalcitonin as a marker of the systemic inflammatory 281 response to infection Novel applications for serum procalcitonin testing in clinical 283 practice Procalcitonin as a diagnostic marker for 285 sepsis: a systematic review and meta-analysis Procalcitonin to guide antibiotic decision 287 making Procalcitonin-guided diagnosis and antibiotic 289 stewardship revisited Procalcitonin in patients with severe coronavirus disease 2019 (COVID-291 19): A meta-analysis Procalcitonin 294 levels predict clinical course and progression-free survival in patients with medullary thyroid 295 cancer